Vanguard Group Inc. Buys 184,537 Shares of 10x Genomics $TXG

Key Points

• Vanguard Group Inc. has increased its stake in 10x Genomics by 1.7%, owning 11,118,086 shares valued at approximately $97.06 million.
• During the first quarter, several hedge funds, including GAMMA Investing LLC and PNC Financial Services Group Inc., significantly increased their holdings in the company.
• 10x Genomics reported earnings of $0.28 per share, surpassing analysts' expectations, with revenue of $172.91 million for the quarter.

Vanguard Group Inc. raised its position in 10x Genomics (NASDAQ:TXG - Free Report) by 1.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,118,086 shares of the company's stock after purchasing an additional 184,537 shares during the period. Vanguard Group Inc. owned 9.09% of 10x Genomics worth $97,061,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in TXG. RA Capital Management L.P. purchased a new stake in shares of 10x Genomics during the 4th quarter valued at $47,092,000. D. E. Shaw & Co. Inc. purchased a new stake in shares of 10x Genomics during the 4th quarter valued at $17,499,000. Two Sigma Investments LP raised its position in shares of 10x Genomics by 291.2% during the 4th quarter. Two Sigma Investments LP now owns 1,319,487 shares of the company's stock valued at $18,948,000 after buying an additional 982,203 shares in the last quarter. ARK Investment Management LLC raised its position in shares of 10x Genomics by 7.5% during the 1st quarter. ARK Investment Management LLC now owns 12,845,713 shares of the company's stock valued at $112,143,000 after buying an additional 901,656 shares in the last quarter. Finally, Two Sigma Advisers LP raised its position in shares of 10x Genomics by 240.6% during the 4th quarter. Two Sigma Advisers LP now owns 1,236,200 shares of the company's stock valued at $17,752,000 after buying an additional 873,200 shares in the last quarter. Hedge funds and other institutional investors own 84.68% of the company's stock.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, CFO Adam Taich sold 22,315 shares of the business's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $307,723.85. Following the transaction, the chief financial officer owned 309,273 shares in the company, valued at approximately $4,264,874.67. The trade was a 6.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Benjamin J. Hindson sold 7,486 shares of the business's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $103,231.94. Following the completion of the transaction, the insider owned 440,888 shares in the company, valued at $6,079,845.52. The trade was a 1.67% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 39,149 shares of company stock worth $539,865. 9.39% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

TXG has been the topic of several research reports. UBS Group raised their price objective on shares of 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a research report on Friday, August 8th. The Goldman Sachs Group lowered their price objective on shares of 10x Genomics from $7.50 to $6.50 and set a "sell" rating on the stock in a research report on Monday, May 12th. Canaccord Genuity Group set a $16.00 target price on shares of 10x Genomics in a research report on Monday, August 11th. Bank of America lifted their target price on shares of 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a research report on Thursday, June 26th. Finally, Morgan Stanley decreased their target price on shares of 10x Genomics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 12th. Six research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, 10x Genomics has an average rating of "Hold" and an average price target of $13.54.

10x Genomics Trading Up 1.9%

Shares of TXG stock traded up $0.26 during mid-day trading on Thursday, reaching $14.28. The stock had a trading volume of 2,342,569 shares, compared to its average volume of 3,155,963. The stock's 50-day moving average price is $12.85 and its two-hundred day moving average price is $10.69. 10x Genomics has a 52-week low of $6.78 and a 52-week high of $24.76. The firm has a market capitalization of $1.78 billion, a PE ratio of -20.40 and a beta of 2.03.

10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.63. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The firm had revenue of $172.91 million for the quarter, compared to analysts' expectations of $139.36 million. During the same quarter in the previous year, the company earned ($0.32) earnings per share. The company's revenue for the quarter was up 12.9% compared to the same quarter last year. 10x Genomics has set its Q3 2025 guidance at EPS. On average, equities research analysts forecast that 10x Genomics will post -1.43 earnings per share for the current year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.